On December 10, 2014, the "Research and Development Seminar on CHA Injection, a Class 1.2 Antitumor New Drug" was organized by the Institute of Materia Medica, Chinese Academy of Medical Sciences and held in Beijing. The participating experts and leaders are as follows:

The "Phase 1 Clinical Trial on the Tolerance and Pharmacokinetic Characteristics of CHA for Injection in Subjects with Advanced Cancer" was approved by the Medical Ethics Committee of Beijing Cancer Hospital on September 3, 2014.

In August 2013, CHA and CHA for injection obtained the clinical trial approval documents from the China Food and Drug Administration (CFDA).

Our company assembled its technical backbones, gave full play to its scientific research advantages, and after long-term research, with the strenuous efforts of the scientific research team led by Wang Li, Yang Huarong, and Wang Zhu, a scientific and detailed experiment on the sensitization of CHA was carried out. And a paper titled "Comprehensive Evaluation of the Non-sensitizing Property of CHA" was published in the authoritative journal "Chinese Journal of Medicinal Guide", which aroused a strong response from relevant people. It opened up new ideas and windows for the treatment and control of cancer and brought good news to cancer patients.

CHA is a common polyphenolic compound, widely present in various fruits, vegetables, and traditional Chinese medicines. It has quite obvious effects in many aspects such as scavenging DPPH free radicals, scavenging oxygen free radicals, and inhibiting lipid peroxidation. CHA extracted from natural plants has a strong reducing power. Its ability to scavenge hydroxyl free radicals is better than that of Vc. When the concentration is 1mg/mL, it can reach 53.18%; its ability to scavenge superoxide anion free radicals is very good, slightly lower than that of Vc. When the concentration is 0.2mg/mL, the scavenging rate is greater than 90%; its ability to scavenge DPPH is higher than that of Vc. When the concentration is 0.2mg/mL, the scavenging rate is greater than 90%. The results show that the antioxidant effect of CHA is stronger than that of Vc, and it should receive sufficient attention. It will be a potential player and a future leader in the field of antioxidation.

Through long-term research, based on establishing the pharmacological, toxicological and pharmacokinetic studies of CHA, Jiuzhang Biotech has developed CHA, a Class 1 new drug in China, and its preparations. In cooperation with renowned universities, we have completed all the pre-clinical research work of this drug, including topic establishment, research on the preparation process of the bulk drug, structure confirmation research, quality research and formulation of quality standards, stability research, selection of packaging materials or containers in direct contact with the drug, research on dosage forms and formulation processes, pharmacology, pharmacodynamics, toxicology, pharmacokinetics, tests on allergic reactions, hemolysis and local irritation, tests on mutagenicity, reproductive toxicity, carcinogenicity, dependence, as well as pharmacokinetic studies, etc.